A consortium of investors led a $140m Series B round in Tidal Vision.

A consortium of investors, including Cambridge SPG, Eni Next, Milliken & Company, KIRKBI, Convent Capital, SWEN Capital Partners, MBX Capital, Oman Investment Authority, led a $140m Series B round in Tidal Vision, a biotechnology company transforming critical industries with chitosan-based chemistries. "We are thrilled to have these strategically aligned capital partners onboard and supportive of accelerating our mission. We've already demonstrated it's possible to make our biomolecular solutions outcompete. Now, we're building infrastructure that'll allow us to better serve customers who operate in critical industries providing the clean water, agriculture production, and materials necessary for everyday life," Craig Kasberg, Tidal Vision CEO.